BIOGEN INC. (BIIB) Return on equity 2016–2025
BIOGEN INC. (BIIB) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
7.1%FY2025 · since FY2016: 30.5% → 7.1%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 7.1% | -2.7 pp |
| FY2024 | 9.8% | +1.9 pp |
| FY2023 | 7.8% | -14.9 pp |
| FY2022 | 22.7% | +8.5 pp |
| FY2021 | 14.3% | -23.1 pp |
| FY2020 | 37.4% | -6.7 pp |
| FY2019 | 44.1% | +10.2 pp |
| FY2018 | 34.0% | +13.8 pp |
| FY2017 | 20.1% | -10.4 pp |
| FY2016 | 30.5% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More BIIB financial trends
BIIB RevenueBIIB Net incomeBIIB Net marginBIIB Gross profitBIIB Gross marginBIIB Operating incomeBIIB Operating marginBIIB Operating cash flowBIIB Free cash flowBIIB Capital expendituresBIIB Stock buybacksBIIB Dividends paidBIIB Total assetsBIIB Total liabilitiesBIIB Shareholders’ equityBIIB overview →